Severe Persistent Asthma
13
0
0
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
88.9%
+2.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Project 2 Airway Potential Hydrogen (pH) in Asthma
Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
Expressions of TRPV1 in Airway of Asthmatics
Severe Asthma Research Program - Wake Forest University
Inhaled Steroids and Control of Severe Asthma
A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma
Prevalence of Hyperventilation Syndrome in Difficult Asthma
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
Bronchoscopy Study for Severe Asthma
Evaluation of Lovastatin in Severe Persistent Asthma
A National Program for Severe Asthma: The Canadian Severe Asthma Network